reports
- Guy Sips
Biotalys EPA issues proposed registration decision for Evoca
We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
- Lynn Hautekeete
Eurocommercial Properties 3Q25 results: Italy continues to outperform
Eurocommercial reports results in line with our expectations at EUR 1.85 direct investment result per share vs. 1.83 KBCSe (+1.1% YoY). The rental income growth accelerated at 3.6% like-for-like (1.7% above inflation) driven by rent reversion, stable (+10bps) vacancy and higher retail sales (+4.1% vs 2.6% in 1H25). The like-for-like growth is mainly driven by the Italian portfolio at +5.1%. The average rent collection dropped from 99.0% to 98.0% coming from the French portfolio (92% in 3Q25). Th...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Thomas Couvreur
- Wim Hoste
- Kristof Samoy
Fugro Good cost control & net debt well controlled, but not out of the...
3Q25 figures showed overall revenues falling -12.6% to €505m well below forecasts. Thanks to solid cost control EBIT landed at €65m considerably above our €51mE and €43m CSS fcst. Following three profit warnings expectations were likely not overly challenging. Given the deep discount valuation we believe today's share price reaction is not necessarily a prelude for 2026 performance. A positive reaction will likely follow but a structural re-rating will only occur once there are clear indications...
- Wim Hoste
Syensqo FIRST LOOK: Divesting Oil & Gas BU to SNF for an EV of € 135m
The announced divestment of the Oil & Gas business unit to SNF was no surprise, as this business had been earmarked previously as non-core and did not fit well with the ESG profile and profitability margins of the remainder of the group. The transaction is fairly small though, with an EV of € 135m. Despite the weak current earnings momentum at Syensqo, we believe that cost efficiency measures and further portfolio streamlining (also Aroma Performance is considered non core) should eventually be ...
- Guy Sips
X Fab Silicon Foundries EV Good 3Q but low order intake, CEO steps dow...
In 3Q25, X-Fab recorded a nice revenues of $ 228.6m, up 11% y/y and up 6% q/q, which is well above the guidance. 4Q25 revenue is expected to come in within the range of $215-225m (KBCSe 219.9m, CSS $ 221.2m) with an EBITDA margin in the range of 22.5% and 25.5% (KBCSe 26.1%, CSS 25.8%). We lower our rating to Hold while maintaining our € 7 Target Price as a negative surprise was the order intake for 3Q25 amounting to a low $ 163m, down 25% y/y and down 21% q/q primarily due to continued in...
- Kristof Samoy
Arcadis Key take-aways analyst call
This morning Arcadis reported numbers (as written in our FRN) which were at P&L level roughly inline with our forecasts but below consensus. FCF was weak at €80m down from €134m in 4Q25 linked to timing of billing milestones and issues linked with the implementation of Oracle at the 2023 IBI acquisition. Before opening we downgraded to Hold (from Accumulate) as the stock rallied considerably since the announcement of a €175m SBB early October. On top we saw no room for outperformance on our numb...
- Jacob Mekhael
- Guy Sips
- Jacob Mekhael
argenx 3Q25 results Vyvgart delivers another CSS beat
argenx' 3Q25 numbers came in solid with Vyvgart sales of $ 1.13b, delivering another beat (approx. 6.8%) on company compiled CSS ($ 1,054.8m). Product revenue consensus for FY25 currently stands at $ 3.93b, which is well within reach as PFS continues to contribute to the launch momentum. argenx reached operating profitability for the 5th consecutive quarter despite a 40% increase in opex. ACCUMULATE maintained.
- Wim Hoste
Recticel FIRST LOOK: 3Q top line below expectations, FY guidance maint...
Recticel saw 3Q revenue decline by 1% which was below our and consensus forecasts. Recticel reiterated FY25 adjusted EBITDA guidance calling for c. 10% growth. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing according to plan. While we still believe in the strategic attractiveness of the insulation market and Recticel's offering, we deem short term valuation multiples are about fair so we maintain our Hold rating and € 11 target pric...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Hoste
- Kristof Samoy
Arcadis 3Q25 broadly in line, no room for upgrades, TP reached & downg...
Arcadis' 3Q25 trading update was broadly in line. Revenues were up organically by 1% (-4.3% FX impact) and landed at €936m (vs. our €939m (+1.2%) and CSS of € 962m (+1.6%)). Operating EBITA stood at €108m in line with our €110m estimate and slightly below €112m CSS. Posted margins are up 20bps in spite of limited revenue growth. Some €7m non operating costs hit the P&L linked to further restructurings in the UK & Australia. BtB of 0.94x (from 1.3x 3Q24) and BL of €3544m up 1.6% y/y org. but down...
- Wim Hoste
Ontex FIRST LOOK: 3Q: -4% LFL revenue, EBITDA -10%, FY guidance kept
Despite a weaker than expected top line (-4% LFL), 3Q adjusted EBITDA dropped less than we expected (-10% y/y) whilst being close to consensus. Ontex reiterated FY25 guidance of € 200-210m adjusted EBITDA whilst we and consensus are more cautious (respectively 6% below the low end of the range and 2% for consensus). Whilst we still believe in the growth prospects of the US business on the back of lower private label penetration and Ontex' challenger status, we cannot be blind for the intensified...
- Wim Hoste
DSM-Firmenich FIRST LOOK: 3Q EBITDA flat, FY guidance lowered; ANH dea...
3Q adj EBITDA was flat which was in line with consensus and slightly below our forecasts. Dsm-firmenich lowered FY25 adjusted EBITDA guidance from around € 2.4bn to around € 2.3bn, due to FX and lowered impact from vitamin prices. Dsm-firmenich now expects a divestment deal on ANH in 4Q. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. We continue to believe that the upcoming separation of the ANH business can be a catalyst to unlock value so we maintain ou...
- Wim Hoste
AB InBev FIRST LOOK: 3Q: weak volumes, EBITDA still up 3.3%; $6bn SBB
3Q volumes decreased by 3.7% organically which was below our and consensus forecasts, while organic adj EBITDA growth of +3.3% outperformed consensus (of +0.9%). ABI reiterated FY25 guidance of 4-8% organic EBITDA growth which is in line with the mid term guidance. Importantly, a $ 6bn share buyback (over 24 months) was announced (as well as a € 0.15 dividend). We still see ABI as the undisputed leader in the beer space, with leading market shares in many markets, ongoing digitization and premiu...
- Wim Hoste
Corbion Feedback 3Q results conference call
Below are the key highlights from the 3Q results conference call. 3Q top line was a bit weaker than expected whilst 3Q adjusted EBITDA increased by 11% organically and was in line with our and consensus expectations. Corbion still expects organic EBITDA growth of over 25% which translates into c. € 207m when taking into account the expected negative $ effect (KBCS & CSS € 206m). We continue to appreciate Corbion for its market leadership in lactic acid and growth opportunities within the existin...
- Livio Luyten
Quest for Growth €1/Share capital return and strategic reset
Quest for Growth announced a strategic reorientation to refocus on its core mission of investing in unquoted growth companies and successful quoted small caps. The Board proposes a €18.7 million capital reduction, distributing €1 net per share to shareholders without cancelling shares, funded by existing cash and the sale of large-cap positions. This move is said to aim to sharpen the fund's profile as a pure growth specialist. The strategy maintains focus on three pillars: Digital, Health, and ...
- Lynn Hautekeete
Aedifica Solid 3Q25 results, all eyes on the BCA
Aedifica reports EPRA earnings 1.3% ahead of our expectations and increases its EPRA EPS guidance by 1.8% to EUR 5.10 per share (excl. transaction costs merger). The key driver behind the outperformance is the rental income. YTD Aedifica has divested EUR 125.0m assets (mainly exit from Sweden). It has replenished the pipeline with EUR 163.0m investments: EUR 105m developments + EUR 58m acquisitions. The pipeline is committed at 6.5% YoC. Q3 had the biggest fair value uplift to date (0.35% and 0....
- Guy Sips
Materialise Medical offsetting headwind in Manufacturing segment
In addition to the positive net result and strong cash flow in 3Q25, we were pleased to note that Materialise's Medical Segment achieved a record quarterly revenue, growing over 10% y/y. This performance stands out against a backdrop of ongoing macroeconomic headwinds, which continued to weigh on its overall revenues—particularly within Manufacturing. Materialise highlighted it further implemented targeted cost control measures designed to protect its operational profitability without compromisi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.